Phase 3Data readout

Hetlioz/Tasimelteon (Melatonin Receptor Agonist)

Delayed Sleep Phase Disorder

VNDAVanda Pharmaceuticals Inc.

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Hetlioz/Tasimelteon (Melatonin Receptor Agonist)
Development stage: Phase 3
Event type: Data readout
Indication: Delayed Sleep Phase Disorder

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for Hetlioz/Tasimelteon (Melatonin Receptor Agonist) in Delayed Sleep Phase Disorder. The expected timing is based on the latest available company guidance and may change.

Development notes

08/05/26:- Ph3 DSPD results expected by end of 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Hetlioz/Tasimelteon (Melatonin Receptor Agonist)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Imsidolimab (IL-36 Inhibitor)

VQW-765

Bysanti™ (milsaperidone)

NEREUS™ (tradipitant)